Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-25T09:13:48.610Z Has data issue: false hasContentIssue false

Will Chemical Packages be the only Future for Biotechnology? Why the Bayer-Monsanto Merger Could be a Good Opportunity to Put Things in the Right Place

Published online by Cambridge University Press:  20 January 2017

Justo Corti Varela*
Affiliation:
Universidad CEU San Pablo, Madrid

Abstract

This section aims to update readers on decisions related to marketing products of modern biotechnology (e.g., GMOs, animal clones) at EU level and on national measures concerning their production. Special attention is devoted to problems of competence between Member States and the EU in regulating biotechnology issues; the institutional dynamics of decision making regarding products derived from modern biotechnology; the relationship between the EFSA and the EU institutions on green biotech-related issues; the evolution of EU regulatory framework and of national attitudes towards the risks and benefits of biotechnology derived products and their production. This section will also delve into the interaction between the EU legislation and WTO law regarding advances in the application of biotechnology within the agri-food value chain.

Type
Reports
Copyright
Copyright © Cambridge University Press 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)